Indicate Solutions, S.L. was set up in 2016 to exploit and commercialise the IP generated by the INDICATE project . The INDICATE project (IN vitro DIagnostic CAncer TEst) was originally conceived in 2013 by Charles Lawrie of Biodonostia, and Luis Liz-Marzán and Marek Gzelczak of CIC biomaGUNE in Donostia-San Sebastián, Spain. They were later joined by researchers from the Univerisity of the Basque Country (UPV) and Polymat.
The concept has received over €1,164K in competitive grants from national and regional governments and with this funding, we have taken this project from the blackboard (i.e. TRL1) to experimentally validating these concepts (i.e. TRL3/4). The IP generated from this project has been granted an EPO patent (EP2016/077267). Indicate Solutions has been granted an exclusive licence to exploit and commercialise this IP.
The INDICATE device concept is a rapid point-of-care (POC) companion diagnostic device to detect cancer-specific mutations from blood (liquid biopsies) in a quick and simple manner.
Global liquid biopsy market will be $4.5 billion by 2020
Cancer liquid biopsy market has a five-year CAGR of 36.2%
Millions funded into companies already
2.78 million potential users worldwide for lung cancer alone
Unique selling points of INDICATE device:
- Single-use disposable
- No laboratory equipment/specialised personnel required
- Rapid (minutes) yes/no answer
- Platform technology rapidly adaptable to new indications including:
- personalised medicine (cancer), infectious disease, environmental monitoring, veterinary use, extreme environments etc.